This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Citrome, L. Search for Related Content PubMed PubMed Citation Articles by Citrome, L. Social Bookmarking                   What's this?

Metabolic Syndrome and Cardiovascular Disease

New York University School of Medicine, Department of Psychiatry, and the Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA, citrome{at}nki.rfmh.org

Metabolic syndrome is a constellation of clinical findings that identify individuals at higher than normal risk of developing diabetes mellitus or cardiovascular disease. There are two principal definitions, one emerging from the American National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, and the other from the World Health Organization. Both definitions share the common elements of abdominal obesity, hypertriglyceridaemia, low HDL-cholesterol, hypertension and abnormal glucose regulation. The syndrome is relatively common across continents, and also among those without marked obesity. It is even more common among patients with major mental health disorders such as schizophrenia. Metabolic syndrome can be used to assess risk for cardiovascular disorder and death, and is an alternative to Framingham Risk Calculations. C-reactive protein may play an additional role in risk prediction. Ongoing monitoring for all components of the metabolic syndrome is necessary. Individuals at high risk require multimodal interventions, including lifestyle interventions and targeted medications as appropriate.

Key Words: metabolic syndrome • cardiovascular disease • schizophrenia • antipsychotics

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. S. Falck, Jichuan Wang, and R. G. Carlson Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis J Psychopharmacol, January 1, 2008; 22(1): 47 - 54. [Abstract] [PDF]

				R. I. Holt Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 199 - 204. [Abstract] [PDF]

				C. Guillot and D. Greenway Recreational ecstasy use and depression J Psychopharmacol, May 1, 2006; 20(3): 411 - 416. [Abstract] [PDF]

				A. C. Parrott MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress J Psychopharmacol, March 1, 2006; 20(2): 147 - 163. [Abstract] [PDF]

				M. M. L. de Win, T. Schilt, L. Reneman, H. Vervaeke, G. Jager, S. Dijkink, J. Booij, and W. van den Brink Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study J Psychopharmacol, March 1, 2006; 20(2): 226 - 235. [Abstract] [PDF]

				C. Bushe, P. Haddad, R. Peveler, and J. Pendlebury The role of lifestyle interventions and weight management in schizophrenia J Psychopharmacol, November 1, 2005; 19(6_suppl): 28 - 35. [Abstract] [PDF]